Growth retardation, malnutrition, and failure to thrive are some of the consequences associated with congenital heart diseases. Several metabolic factors such as hypoxia, anoxia, and several genetic factors are believed to alter the energetics of the heart. Timely diagnosis and patient management is one of the major challenges faced by the clinicians in understanding the disease and provide better treatment options. Metabolic profiling has shown to be potential diagnostic tool to understand the disease.
Objective:
The present experiment was designed as a single center observational pilot study to classify and create diagnostic metabolic signatures associated with the energetics of congenital heart disease in cyanotic and acyanotic groups.
Methods:
Metabolic sera profiles were obtained from 35 patients with cyanotic congenital heart disease (TOF) and 23 patients with acyanotic congenital heart disease (ASD and VSD) using high resolution 1D 1H NMR spectra. Univariate and multivariate statistical analysis were performed to classify particular metabolic disorders associated with cyanotic and acyanotic heart disease.
Results:
The results show dysregulations in several metabolites in cyanotic CHD patients versus acyanotic CHD patients. The discriminatory metabolites were further analyzed with area under receiver operating characteristic (AUROC) curve and identified four metabolic entities (i.e. mannose, hydroxyacetone, myoinositol, and creatinine) which could differentiate cyanotic CHDs from acyanotic CHDs with higher specificity.
Conclusion:
An untargeted metabolic approach proved to be helpful for the detection and distinction of disease-causing metabolites in cyanotic patients from acyanotic ones and can be useful for designing better and personalized treatment protocol.
ShinebourneEABabu-NarayanSVCarvalhoJS.Tetralogy of Fallot: from fetus to adult. Heart2006; 92: 1353–1359.
2.
TeohKHMickleDAWeiselRD, et al. Effect of oxygen tension and cardiovascular operations on the myocardial antioxidant enzyme activities in patients with tetralogy of Fallot and aorta-coronary bypass. J Thorac Cardiovasc Surg1992; 104: 159–164.
3.
MehriziADrashA.Growth disturbance in congenital heart disease. J Pediatr1962; 61: 418–429.
4.
FeldtRHStricklerGBWeidmanWH.Growth of children with congenital heart disease. Am J Dis Children1969; 117: 573–579.
5.
MitchellIMLoganRWPollockJC, et al. Nutritional status of children with congenital heart disease. Heart1995; 73: 277–283.
6.
SchwarzSMGewitzMHSeeCC, et al. Enteral nutrition in infants with congenital heart disease and growth failure. Pediatrics1990; 86: 368–373.
7.
PittmanJGCohenP.The pathogenesis of cardiac cachexia. New Engl J Med1964; 271: 403–409.
8.
YahavJAvigadSFrandM, et al. Assessment of intestinal and cardiorespiratory function in children with congenital heart disease on high-caloric formulas. J Pediatr Gastroenterol Nutr1985; 4: 778–785.
9.
CavellB.Gastric emptying in infants with congenital heart disease. Acta Paediatr1981; 70: 517–520.
10.
RothbaumRJ.Pediatric nutrition: theory and practice. Am J Dis Child1987; 141: 1209–1209.
11.
EhlersKH.Growth failure in association with congenital heart disease. Pediatr Ann1978; 7: 750–759.
12.
KraussANAuldPA.Metabolic rate of neonates with congenital heart disease. Arch Dis Child1975; 50: 539–541.
13.
GervasioMRBuchananCN.Malnutrition in the pediatric cardiology patient. Crit Care Nurs Q1985; 8: 49–56.
14.
LeitchCAKarnCAPeppardRJ, et al. Increased energy expenditure in infants with cyanotic congenital heart disease. J Pediatr1998; 133: 755–760.
15.
CameronJWRosenthalAOlsonAD.Malnutrition in hospitalized children with congenital heart disease. Arch Pediatr Adolesc Med1995; 149: 1098–1102.
16.
KriegerI.Growth failure and congenital heart disease: energy and nitrogen balance in infants. Am J Dis Child1970; 120: 497–502.
17.
MenonGPoskittEM.Why does congenital heart disease cause failure to thrive?Arch Dis Child1985; 60: 1134–1139.
18.
Miall-AllenVMKempGJRajagopalanB, et al. Magnetic resonance spectroscopy in congenital heart disease. Heart1996; 75: 614–619.
19.
AdatiaIKempGJTaylorDJ, et al. Abnormalities in skeletal muscle metabolism in cyanotic patients with congenital heart disease: a 31P nuclear magnetic resonance spectroscopy study. Clin Sci1993; 85: 105–109.
20.
AckermanJBorePGadianD, et al. Nmr studies of metabolism in perfused organs. Philos Trans R Soc Lond B Biol Sci1980; 289: 425–436.
21.
GadianDGHoultDIRaddaGK, et al. Phosphorus nuclear magnetic resonance studies on normoxic and ischemic cardiac tissue. Proc Natl Acad Sci USA1976; 73: 4446–4448.
22.
BaileyIAWilliamsSRRaddaGK, et al. Activity of phosphorylase in total global ischaemia in the rat heart a phosphorus-31 nuclear-magnetic-resonance study. Biochem J1981; 196: 171–178.
23.
VimalSRanjanRYadavS, et al. Serum Metabolomics Profiling to Identify Novel Biomarkers for Cyanotic Heart Disease. Biomed Pharmacol J2021; 14: 81–94.
24.
MorotomiNSaitohMIshiiN, et al. Relation between change in exercise capacity and change in blood amino acids in patients with chronic heart failure. J Phys Ther Sci2017; 29: 425–431.
25.
AquilaniRLa RovereMTCorbelliniD, et al. Plasma amino acid abnormalities in chronic heart failure. Mechanisms, potential risks and targets in human myocardium metabolism. Nutrients2017; 9: 1251.
26.
ZhaoL-LQiuX-JWangW-B, et al. NMR metabolomics and random forests models to identify potential plasma biomarkers of blood stasis syndrome with coronary heart disease patients. Front Physiol2019; 10: 1109.
27.
DrakeKJSidorovVYMcGuinnessOP, et al. Amino acids as metabolic substrates during cardiac ischemia. Exp Biol Med2012; 237: 1369–1378.
28.
NishimuraMTanakaHHommaN, et al. Ionic mechanisms of the depression of automaticity and conduction in the rabbit atrioventricular node caused by hypoxia or metabolic inhibition and protective action of glucose and valine. Am J Cardiol1989; 64: 24J–28J.
29.
IchiharaANodaCOgawaK.Control of leucine metabolism with special reference to branched-chain amino acid transaminase isozymes. Adv Enzyme Regul1973; 11: 155–166.
30.
(a) SansRMJollyWWHarrisRA. Studies on the regulation of leucine catabolism: mechanism responsible for oxidizable substrate inhibition and dichloroacetate stimulation of leucine oxidation by the heart. Arch Biochem Biophys1980; 200: 336–345; (b) ParkerPJRandlePJ. Active and inactive forms of branched-chain 2-oxoacid dehydrogenase complex in rat heart and skeletal muscle. FEBS Lett1980; 112: 186–190.
31.
(a) KaoRRannelsDEMorganHE.Effects of anoxia and ischemia on protein synthesis in perfused rat hearts. Circ Res1976; 38(Suppl 1): I124–130; (b) TaegtmeyerHPetersonMBRagavanVV, et al. De novo alanine synthesis in isolated oxygen-deprived rabbit myocardium. J Biol Chem1977; 252: 5010–5018.
32.
(a) PlsarenkoOIBaranovAVAleshinOI, et al. Features of myocardial metabolism of some amino acids and ammonia in patients with coronary artery disease. Eur Heart J1989; 10: 209–217; (b) CarlstenAHallgrenBJagenburgR, et al. Myorcardial metabolism of glucose, lactic acid, amino acids and fatty acids in healthy human individuals at rest and at different work loads. Scand J Clin Lab Invest1961; 13: 418–428.
33.
(a) TaegtmeyerHLeschM. Altered protein and amino acid metabolism in myocardial hypoxia and ischemia. In: WildenthalK (ed.) Degradative processes in heart and skeletal muscle. New York: Elsevier/North Holland Biomedical Press, 1980, pp.347–360; (b) PeuhkurinenKJTakalaTENuutinenEM, et al. Tricarboxylic acid cycle metabolites during ischemia in isolated perfused rat heart. Am J Physiol1983; 244: H281–H288.
34.
MatsuokaSJarmakaniJMYoungHH, et al. The effect of glutamate on hypoxic newborn rabbit heart. J Mol Cell Cardiol1986; 18: 897–906.
35.
ModiPSuleimanMSReevesBC, et al. Free amino acids in hearts of pediatric patients with congenital heart disease: the effects of cyanosis, age, and pathology. Ann Thorac Surg2006; 81: 943–949.
36.
(a) KrishnanNDickmanMBBeckerDF.Proline modulates the intracellular redox environment and protects mammalian cells against oxidative stress. Free Radic Biol Med2008; 44: 671–681; (b) PhangJMDonaldSPPandhareJ, et al. The metabolism of proline, a stress substrate, modulates carcinogenic pathways. Amino Acids2008; 35: 681–690.
37.
(a) FanYLiYChenY, et al. Comprehensive metabolomic characterization of coronary artery diseases. J Am Coll Cardiol2016; 68: 1281–1293; (b) SansburyBEDeMartinoAMXieZ, et al. Metabolomic analysis of pressure-overloaded and infarcted mouse hearts. Circ Heart Fail2014; 7: 634–642.
38.
LiangXZhangLNatarajanSK, et al. Proline mechanisms of stress survival. Antioxid Redox Signal2013; 19: 998–1011.
39.
MishraRCTripathySDesaiKM, et al. Nitric oxide synthase inhibition promotes endothelium-dependent vasodilatation and the antihypertensive effect of L-serine. Hypertension2008; 51: 791–796.
40.
KoppleJD.Phenylalanine and tyrosine metabolism in chronic kidney failure. J Nutr2007; 137: 1586S–1590S; discussion 1597S.
41.
(a) MurrCGrammerTBMeinitzerA, et al. Immune activation and inflammation in patients with cardiovascular disease are associated with higher phenylalanine to tyrosine ratios: the ludwigshafen risk and cardiovascular health study. J Amino Acids2014; 2014:783730 (b) MehtaALiuCNayakA, et al. Untargeted high-resolution plasma metabolomic profiling predicts outcomes in patients with coronary artery disease. PLoS One2020; 15: e0237579; (c) NathanCFMurrayHWWiebeME, et al. Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J Exp Med1983; 158: 670–689.
42.
(a) KoenigW. High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy. Int J Cardiol2013; 168: 5126–5134; (b) ShitaraJOgitaMWadaH, et al. Clinical impact of high-sensitivity C-reactive protein during follow-up on long-term adverse clinical outcomes in patients with coronary artery disease treated with percutaneous coronary intervention. J Cardiol2019; 73: 45–50.
43.
LopaschukGDJaswalJS.Energy metabolic phenotype of the cardiomyocyte during development, differentiation, and postnatal maturation. J Cardiovasc Pharmacol2010; 56: 130–140.
44.
(a) LopaschukGDBelkeDDGambleJ, et al. Regulation of fatty acid oxidation in the mammalian heart in health and disease. Biochim Biophys Acta1994; 1213:263–276; (b) NeelyJRMorganHE. Relationship between carbohydrate and lipid metabolism and the energy balance of heart muscle. Ann Rev Physiol1974; 36: 413–459.
45.
(a) LopaschukGDUssherJRFolmesCDL, et al. Myocardial fatty acid metabolism in health and disease. Physiol Rev1972; 90: 207–258; (b) NeelyJRRovettoMJOramJF. Myocardial utilization of carbohydrate and lipids. Prog Cardiovasc Dis1972; 15: 289-329.
46.
BodiVSanchisJMoralesJM, et al. Metabolomic profile of human myocardial ischemia by nuclear magnetic resonance spectroscopy of peripheral blood serum: a translational study based on transient coronary occlusion models. J Am Coll Cardiol2012; 59: 1629–1641.
47.
JaswalJSKeungWWangW, et al. Targeting fatty acid and carbohydrate oxidation–a novel therapeutic intervention in the ischemic and failing heart. Biochim Biophys Acta2011; 1813: 1333–1350.
48.
LiuXGaoJChenJ, et al. Identification of metabolic biomarkers in patients with type 2 diabetic coronary heart diseases based on metabolomic approach. Sci Rep2016; 6: 30785–30813.
49.
UelandPM.Choline and betaine in health and disease. J Inherit Metab Dis2011; 34: 3–15.
50.
SteengeGRVerhoefPKatanMB.Betaine supplementation lowers plasma homocysteine in healthy men and women. J Nutr2003; 133: 1291–1295.
51.
MezJDaneshvarDHKiernanPT, et al. Clinicopathological evaluation of chronic traumatic encephalopathy in players of American football. JAMA2017; 318: 360–370.
52.
GeerEBIslamJBuettnerC.Mechanisms of glucocorticoid-induced insulin resistance: focus on adipose tissue function and lipid metabolism. Endocrinol Metab Clin North Am2014; 43: 75–102.
53.
(a) OuyangXDaiYWenJL, et al. 1H NMR-based metabolomic study of metabolic profiling for systemic lupus erythematosus. Lupus2011; 20: 1411–1420; (b) GuleriaAMisraDPRawatA, et al. NMR-based serum metabolomics discriminates Takayasu arteritis from healthy individuals: a proof-of-principle study. J Proteome Res2015; 14: 3372–3381; (c) SunLHuWLiuQ, et al. Metabonomics reveals plasma metabolic changes and inflammatory marker in polycystic ovary syndrome patients. J Proteome Res2012; 11: 2937–2946.
54.
CalderPC.Polyunsaturated fatty acids and inflammatory processes: new twists in an old tale. Biochimie2009; 91: 791–795.
55.
(a) SalmonJAHiggsGA. Prostaglandins and leukotrienes as inflammatory mediators. Br Med Bull1987; 43(2): 285–296; (b) MarinettiGV. Disorders of lipid metabolism. Springer Science & Business Media.
56.
(a) FrangogiannisNGSmithCWEntmanML.The inflammatory response in myocardial infarction. Cardiovasc Res2002; 53: 31–47; (b) BertonGCordianoRPalmieriR, et al. C-reactive protein in acute myocardial infarction: association with heart failure. Am Heart J2003; 145: 1094–1101; (c) SaxenaARussoIFrangogiannisNG. Inflammation as a therapeutic target in myocardial infarction: learning from past failures to meet future challenges. Transl Res2016; 167: 152–166.
57.
BizzarriMFusoADinicolaS, et al. Pharmacodynamics and pharmacokinetics of inositol(s) in health and disease. Expert Opin Drug Metab Toxicol2016; 12: 1181–1196.
58.
McKirnanMDIchikawaYZhangZ, et al. Metabolomic analysis of serum and myocardium in compensated heart failure after myocardial infarction. Life Sci2019; 221: 212–223.
59.
VignoliATenoriLGiustiB, et al. Differential network analysis reveals metabolic determinants associated with mortality in acute myocardial infarction patients and suggests potential mechanisms underlying different clinical scores used to predict death. J Proteome Res2020; 19: 949–961.
60.
RodríguezCBorzęckaWSattlerJH, et al. Steric vs. Electronic effects in the Lactobacillus brevis ADH-catalyzed bioreduction of ketones. Org Biomol Chem2014; 12: 673–681.
61.
PetersenTHWilliamsTNuwayhidN, et al. Postmortem detection of isopropanol in ketoacidosis. J Forensic Sci2012; 57: 674–678.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
